Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Humans May Benefit from Canine Bladder Cancer Assay

By LabMedica International staff writers
Posted on 23 Jun 2014
A unique group of proteins have been identified that indicate the presence of transitional cell carcinoma, the most common cause of bladder cancer and may lead to a new assay which could better diagnose this disease in both dogs and humans. More...


An improved assay to detect this serious disease much earlier in both animals and humans should be possible, and may even become affordable enough that it could be used as an over-the-counter product to test urine.

Scientists at Oregon State University (Corvallis, OR, USA) analyzed the canine urinary proteome as a noninvasive diagnostic tool for transitional cell carcinoma (TCC) identification. Urine was collected from 12 dogs in three cohorts (healthy, urinary tract infection, TCC) and analyzed using liquid chromatography tandem mass spectrometry (LC–MS/MS).

Peptide sample were analyzed using a linear ion trap combined with a Fourier transform ion cyclotron resonance (LTQ-FT) mass spectrometer (Thermo Scientific; Waltham, MA, USA) coupled to a nanoAcquity Ultra Performance Liquid Chromatography (UPLC) system (Waters, Milford, MA, USA). The scientists also performed immunoblots on a cellular fractions and polymerase chain reaction for detection of bacterial infections.

The team used the science of proteomics to identify 96 proteins that appear related to transitional cell carcinoma. This is a fairly common cancer in dogs, often as a result of exposure to pesticides, herbicides, and poor quality foods; and in humans is closely related to smoking. The presence of four proteins, macrophage capping protein, peroxiredoxin 5, heterogeneous nuclear ribonucleoproteins A2/B, and apolipoprotein A1, was confirmed via immunoblotting. The groups of proteins identified in the study were 90% accurate in diagnosing cancer, and investigators say they hope to improve upon that with continued studies.

The authors concluded that their novel approach to biomarker discovery can be applied to studies in humans to determine whether the same biomarkers can predict TCC in humans and dogs, and if not, which biomarkers are unique to urine from human TCC patients. The study was published in the June 2014 issue of the journal Analytical Biochemistry.

Related Links:

Oregon State University 
Thermo Scientific
Waters



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.